“It seems like podcasts really are a good way for people to learn about even a complex topic like this,” says Stacy Loeb, MD, MSc.
In this video, Stacy Loeb, MD, MSc, and Veda Giri, MD, discuss the findings of the paper, “Usefulness of podcasts to provide public education on prostate cancer genetics,” which was published in Prostate Cancer and Prostatic Diseases (https://rdcu.be/c3UEl).New episodes of the podcast discussed in the study will drop on Tuesdays (https://open.spotify.com/show/4FYxW2zUgJmW8wkVbiOXBb?si=dca177dda31443f6).
Giri is division chief of Clinical Cancer Genetics for Yale Cancer Center and Smilow Cancer and assistant director of Clinical Cancer Genetics for Yale Cancer Center, New Haven, Connecticut. Loeb is a professor in the departments of urology and population health at the NYU Grossman School of Medicine, New York City, New York.
Loeb: We wanted to make sure that this podcast series was really valuable, and there actually really haven't been a lot of scientific studies testing the utility of podcasts as an educational tool. It seems self-evident that something like this would be educational, but you don't really know. So we did a prospective study with participants from across the US. One group was patients with a history of prostate cancer. The other group was men and women with no specific cancer history. In both groups, we had them listen to the podcasts. They gave very high ratings in terms of usefulness, and they were able to correctly answer genetic questions after listening. So it seems like podcasts really are a good way for people to learn about even a complex topic like this.
Giri: Yes, and we're hopeful that that kind of data, when you actually study it, supports the potential for expanding on utilization of podcasts for dissemination of information about genetic testing for prostate cancer, for hereditary cancer testing, potentially even across different languages so that we really can start to bring this across populations. I think our data support that, and so we're very excited about that.
This transcript was edited for clarity.
Targeted radiation plus systemic therapy combo shows promise in mHSPC
March 18th 2024"The combination of highly potent systemic therapy and targeted radiation has shown impressive results in maintaining low PSA levels after testosterone recovery, offering hope for improved outcomes in these patients, but further studies are still needed to determine the best regimen," says Amar U. Kishan, MD.
Relugolix plus radiotherapy shows safety, efficacy in prostate cancer
March 14th 2024“Remarkably, relugolix demonstrated a faster return to baseline testosterone levels compared [with] traditional therapies, a crucial aspect for patients' quality of life post-treatment," says Daniel E. Spratt, MD.